Farmas USA

• Conatus Pharmaceuticals (NASDAQ:CNAT) is up 4% premarket on light volume in response to its announcement that results from preclinical studies of liver disease candidate IDN-7314 have just been published in Toxicological Sciences. 
• The data suggest that a pan-caspase inhibitor could potentially reduce excessive clotting in patients with severe liver disease such as primary sclerosing cholangitis (PSC), an Orphan Drug indication.
• IDN-7314 is an orally available pan-caspase protease inhibitor designed to reduce the activity of enzymes that play a key role in inflammation and cell death (apoptosis). The FDA designated the candidate an Orphan Drug for PSC in June 2017 followed by the EMA four months late

RIGL Market Cap  595.99M           Gains On FDA Approval      

As mentioned above, Rigel Pharmaceuticals is having a strong start to the trading session after announcing that the FDA has approved one of its treatments. In a press release issued a couple of hours before the market lose yesterday, the company announced that the United States Food and Drug Administration (FDA) has approved TAVALISSE™ for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had insufficient response to a previous treatment.

https://cnafinance.com/rigel-pharmaceuticals-rigl-stock-gaining-on-fda-approval/19062

RGLS

trata de arrancarlos por diosss trata de arrancarlo !! 

edito: nah, la tiran de nuevo ... WTF WTF WTF!

CNAT

1K cromos más a 3.78  media 3.7331

MLNT

Unas pocas más, 450 a 7.15 solo me han dado 301 en 1hr.

CNAT  https://finance.yahoo.com/news/conatus-pharmaceuticals-idn-7314-pan-113000834.html?.tsrc=rss

TGTX HZNP KERX

Dale dale dale!!!!

Jajjaaaaj q bueno